Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer
Completed
- Conditions
- Prostatic NeoplasmsQuality of Life
- Registration Number
- NCT02854982
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
To study the quality of life of patients with prostate cancer at a distance from their care at a time when they are supposed to have taken a "normal" life and compared to subjects without cancer prostate of the same age.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 900
Inclusion Criteria
- prostate cancer diagnosed from 1 December 2011 to 31 December 2014
- under 75 and residing in the Hérault department at diagnosis
- recruited in the EPICAP study
Exclusion criteria:
- having relapsed in the range
- non-exposed group:
Inclusion Criteria:
- controls (without prostate cancer) recruited in the EPICAP study
- matched to cases on age (5 years)
- residing in the Hérault department
Exclusion criteria:
- diagnosis of prostate cancer set in the range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EORTC Quality of Life Questionnaire - Core 30 Score (EORTC QLQ-C30 Score) 3 years from diagnosis for cases of prostate cancer and from recruitment for controls
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence long-term quality of life in prostate cancer survivors compared to controls?
How does standard therapeutic management of prostate cancer impact biomarkers associated with quality of life over 3 years?
Are there specific biomarkers that predict differential quality of life outcomes in prostate cancer patients post-treatment?
What are the long-term adverse events associated with usual care for prostate cancer and how are they managed?
How does the quality of life in NCT02854982 compare to other observational studies on prostate cancer management?